Trade-Ideas LLC identified

Celgene

(

CELG

) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Celgene as such a stock due to the following factors:

  • CELG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $512.8 million.
  • CELG traded 56,242 shares today in the pre-market hours as of 9:23 AM.
  • CELG is up 2.2% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CELG with the Ticky from Trade-Ideas. See the FREE profile for CELG NOW at Trade-Ideas

More details on CELG:

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. CELG has a PE ratio of 52. Currently there are 14 analysts that rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Celgene has been 4.2 million shares per day over the past 30 days. Celgene has a market cap of $83.6 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.60 and a short float of 1.1% with 1.54 days to cover. Shares are down 11.3% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Celgene as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:

  • CELG's revenue growth has slightly outpaced the industry average of 20.2%. Since the same quarter one year prior, revenues rose by 20.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • Net operating cash flow has increased to $974.90 million or 13.82% when compared to the same quarter last year. In addition, CELGENE CORP has also modestly surpassed the industry average cash flow growth rate of 6.25%.
  • The gross profit margin for CELGENE CORP is currently very high, coming in at 97.01%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 31.88% trails the industry average.
  • CELGENE CORP has improved earnings per share by 15.1% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CELGENE CORP reported lower earnings of $1.94 versus $2.40 in the prior year. This year, the market expects an improvement in earnings ($5.70 versus $1.94).
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500, but is less than that of the Biotechnology industry average. The net income increased by 11.4% when compared to the same quarter one year prior, going from $718.90 million to $800.70 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.